



**UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office**

Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

APPLICATION NO. 8	FILING DATE 97	LYMAN FIRST NAMED INVENTOR	S	ATTORNEY-DOCKET NO.
-------------------	----------------	----------------------------	---	---------------------

HM31/1221

LAW DEPARTMENT  
IMMUNEX CORPORATION  
51 UNIVERSITY STREET  
SEATTLE WA 98101

KERR, JEXAMINER

ART. UNIT

PAPER NUMBER

12/21/98

DATE MAILED:

**Please find below and/or attached an Office communication concerning this application or proceeding.**

**Commissioner of Patents and Trademarks**

# Office Action Summary

Application No.  
**08/994,468**

Applicant(s)  
**Lyman et al.**

Examiner  
**Janet M. Kerr**

Group Art Unit  
**1651**



☒ Responsive to communication(s) filed on Dec 19, 1997

☐ This action is **FINAL**.

☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11; 453 O.G. 213.

A shortened statutory period for response to this action is set to expire 3 month(s), or thirty days, whichever is longer, from the mailing date of this communication. Failure to respond within the period for response will cause the application to become abandoned. (35 U.S.C. § 133). Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

## Disposition of Claims

☒ Claim(s) 1-8 is/are pending in the application.

Of the above, claim(s) \_\_\_\_\_ is/are withdrawn from consideration.

☐ Claim(s) \_\_\_\_\_ is/are allowed.

☒ Claim(s) 1-8 is/are rejected.

☐ Claim(s) \_\_\_\_\_ is/are objected to.

☐ Claims \_\_\_\_\_ are subject to restriction or election requirement.

## Application Papers

☒ See the attached Notice of Draftsperson's Patent Drawing Review, PTO-948.

☐ The drawing(s) filed on \_\_\_\_\_ is/are objected to by the Examiner.

☐ The proposed drawing correction, filed on \_\_\_\_\_ is ☐ approved ☐ disapproved.

☐ The specification is objected to by the Examiner.

☐ The oath or declaration is objected to by the Examiner.

## Priority under 35 U.S.C. § 119

☐ Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).

☐ All ☐ Some\* ☐ None of the CERTIFIED copies of the priority documents have been  
☐ received.

☐ received in Application No. (Series Code/Serial Number) \_\_\_\_\_.

☐ received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

\*Certified copies not received: \_\_\_\_\_

☐ Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).

## Attachment(s)

☐ Notice of References Cited, PTO-892

☒ Information Disclosure Statement(s), PTO-1449, Paper No(s). 3

☐ Interview Summary, PTO-413

☒ Notice of Draftsperson's Patent Drawing Review, PTO-948

☐ Notice of Informal Patent Application, PTO-152

— SEE OFFICE ACTION ON THE FOLLOWING PAGES —

### **DETAILED ACTION**

The preliminary amendment, and Information Disclosure Statement, filed on 12/19/97, has been entered.

Applicants should note that the numbering of claims is not accordance with 37 CFR 1.126 which requires the original numbering of the claims to be preserved throughout the prosecution. When claims are canceled, the remaining claims must not be renumbered. When new claims are presented, they must be numbered consecutively beginning with the number next following the highest numbered claims previously presented (whether entered or not).

Misnumbered claims 50-55 have been renumbered 3-8.

Claims 1-8 are being examined on the merits.

### ***Specification***

The disclosure is objected to because of the following informalities: on page 1, line 11, the phrase "now pending" should be changed to "now abandoned" to reflect the updated status of application 08/444,627.

Appropriate correction is required.

### ***Double Patenting***

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 1-8 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-17 of U.S. Patent No. 5,843,423 in view of Tsukamoto *et al.* (U.S. Patent No 5,061,620, 1991). The claims of the instant invention are drawn to hematopoietic cell expansion media comprising cell growth media, flt3-ligand and an additional growth factor. The claims of the instant invention differ from those in U.S. Patent No. 5,843,423 in that the composition of the instant invention is drawn to a formulation for *in vitro* cell expansion while those in '423 are drawn to methods of using the formulation *in vivo* for the same purpose, i.e., hematopoietic cell expansion. In view of the teachings of Tsukamoto *et al.* (see, e.g., column 20, lines 21-33) that media formulations containing growth factors are suitable for hematopoietic cell expansion, one of ordinary skill in the art would have had a high expectation that the growth factor formulations which stimulate *in vivo* cell expansion would also stimulate *in vitro* cell expansion. Thus, it would have been obvious to modify the formulations administered to patients for use in cell culture methodologies.


No claims are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Janet M. Kerr whose telephone number is (703) 305-4055. Should the examiner be unavailable, inquiries should be directed to Michael Wityshyn, Supervisory Primary Examiner of Art Unit 1651, at (703) 308-4743. Papers related to this application may be submitted to Group 1600 by facsimile transmission. Papers should be faxed to Group 1600 via the PTO Fax Center located in Crystal Mall 1. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). The CM1 Fax Center number is (703) 305-7401. Any inquiry of a general nature or relating to the status of this application should be directed to the Group 1600 receptionist whose telephone number is (703) 308-0196.

Application/Control Number: 08/994,468  
Art Unit: 1651

Page 4

The Group and/or Art Unit location of your application in the PTO has changed. To aid in correlating any papers for this application, all further correspondence regarding this application should be directed to Group Art Unit 1651.



Janet M. Kerr, Ph.D.  
Patent Examiner  
Group 1600  
December 18, 1998



DAVID M. NAFF  
PRIMARY EXAMINER  
ART UNIT 1651